{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:19:32Z","timestamp":1794028772175,"version":"4.8.0"},"reference-count":138,"publisher":"Society for Neuroscience","issue":"46","content-domain":{"domain":["jneurosci.org"],"crossmark-restriction":true},"short-container-title":["J. Neurosci."],"accepted":{"date-parts":[[2025,8,26]]},"published-print":{"date-parts":[[2025,11,12]]},"abstract":"<jats:p>\n                    Apolipoprotein E (APOE) is the major lipid transport protein in the brain. Produced primarily by astrocytes and microglia, it delivers cholesterol and other lipids for membrane repair, synaptic maintenance, and immune regulation. Through interactions with specific lipid receptors, APOE maintains neuronal and vascular health. The\n                    <jats:italic>APOE<\/jats:italic>\n                    \u03b54 allele (APOE4), carried by approximately one-quarter of the population, has an altered protein conformation, which reduces lipid transport efficiency and modifies receptor binding. These changes disrupt lipid homeostasis, increase risk of chronic unresolved neuroinflammation and vascular inflammation, and cause breakdown of the blood\u2013brain barrier (BBB), thus increasing neuronal vulnerability to disease pathology and elevating risk for Alzheimer's disease (AD). In this review, we organize the effects of APOE4 into three interconnected \u201chits\u201d that modulate disease progression: disrupted lipid handling, neurovascular inflammation, and neuronal dysfunction. These interconnected hits help explain why amyloid- and tau-directed therapies alone have modest success in treating AD, particularly in APOE4 carriers. We review emerging APOE-related therapeutic strategies designed to address these mechanisms directly, including structure correctors to restore normal protein folding, agents that enhance lipidation and receptor-mediated lipid transport, approaches that modulate downstream inflammatory responses, and gene therapies aimed at isoform switching or allele silencing. By aligning therapeutic strategies with specific aspects of APOE4 biology, such approaches have the potential to provide broader and safer benefits, complement existing disease-modifying therapies, and improve outcomes for individuals at heightened genetic risk of AD.\n                  <\/jats:p>","DOI":"10.1523\/jneurosci.1388-25.2025","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T19:51:46Z","timestamp":1762977106000},"page":"e1388252025","update-policy":"https:\/\/doi.org\/10.1523\/jneurosci.crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["APOE-Targeted Therapeutics for Alzheimer's Disease"],"prefix":"10.1523","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2483-649X","authenticated-orcid":false,"given":"Hussein N.","family":"Yassine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristelle","family":"Hugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"O'Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7070-1805","authenticated-orcid":false,"given":"Isaiah O.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0134-7586","authenticated-orcid":false,"given":"Lance A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3054-9374","authenticated-orcid":false,"given":"Julia","family":"TCW","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4161-2498","authenticated-orcid":false,"given":"Kassandra","family":"Kisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2529-8785","authenticated-orcid":false,"given":"Ornit","family":"Chiba-Falek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"393","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"2025111212300798000_45.46.e1388252025.1","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2014.172"},{"key":"2025111212300798000_45.46.e1388252025.2","doi-asserted-by":"crossref","first-page":"e2806","DOI":"10.1002\/brb3.2806","article-title":"Evidence of emerging BBB changes in mid-age apolipoprotein E epsilon-4 carriers","volume":"12","author":"Alruwais","year":"2022","journal-title":"Brain Behav"},{"key":"2025111212300798000_45.46.e1388252025.3","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14907"},{"key":"2025111212300798000_45.46.e1388252025.4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2018.09.011","article-title":"Novel ABCA1 peptide agonists with antidiabetic action","volume":"480","author":"Azhar","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"2025111212300798000_45.46.e1388252025.5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s42003-024-05767-9","article-title":"Rescue of ApoE4-related lysosomal autophagic failure in Alzheimer\u2019s disease by targeted small molecules","volume":"7","author":"Balasubramaniam","year":"2024","journal-title":"Commun Biol"},{"key":"2025111212300798000_45.46.e1388252025.6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3233\/JAD-150029","article-title":"The continuing failure of bexarotene in Alzheimer's disease mice","volume":"46","author":"Balducci","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"2025111212300798000_45.46.e1388252025.7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221137"},{"key":"2025111212300798000_45.46.e1388252025.8","doi-asserted-by":"publisher","DOI":"10.1038\/nature11087"},{"key":"2025111212300798000_45.46.e1388252025.9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/MOL.0000000000000258","article-title":"ABCA1 agonist peptides for the treatment of disease","volume":"27","author":"Bielicki","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"2025111212300798000_45.46.e1388252025.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05439-w"},{"key":"2025111212300798000_45.46.e1388252025.11","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5198-13.2014"},{"key":"2025111212300798000_45.46.e1388252025.12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166195"},{"key":"2025111212300798000_45.46.e1388252025.13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3233\/JAD-160467","article-title":"ABCA1 agonist reverses the ApoE4-driven cognitive and brain pathologies","volume":"54","author":"Boehm-Cagan","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"2025111212300798000_45.46.e1388252025.14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40478-016-0339-y","article-title":"The relationship between complement factor C3, APOE \u03b54, amyloid and tau in Alzheimer\u2019s disease","volume":"4","author":"Bonham","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"2025111212300798000_45.46.e1388252025.15","doi-asserted-by":"publisher","DOI":"10.1038\/37635"},{"key":"2025111212300798000_45.46.e1388252025.16","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R700014-JLR200"},{"key":"2025111212300798000_45.46.e1388252025.17","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.090973"},{"key":"2025111212300798000_45.46.e1388252025.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2015.10.010"},{"key":"2025111212300798000_45.46.e1388252025.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(03)00361-0"},{"key":"2025111212300798000_45.46.e1388252025.20","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1016\/S0021-9258(19)39374-3","article-title":"A calcium-dependent mechanism for associating a soluble arachidonoyl-hydrolyzing phospholipase A2 with membrane in the macrophage cell line RAW 264.7","volume":"265","author":"Channon","year":"1990","journal-title":"J Biol Chem"},{"key":"2025111212300798000_45.46.e1388252025.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.11.016"},{"key":"2025111212300798000_45.46.e1388252025.22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.276162"},{"key":"2025111212300798000_45.46.e1388252025.23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0914984107"},{"key":"2025111212300798000_45.46.e1388252025.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2020.10.008"},{"key":"2025111212300798000_45.46.e1388252025.25","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00473-0"},{"key":"2025111212300798000_45.46.e1388252025.26","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-015-9627-8"},{"key":"2025111212300798000_45.46.e1388252025.27","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12385)"},{"key":"2025111212300798000_45.46.e1388252025.28","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0173-2"},{"key":"2025111212300798000_45.46.e1388252025.29","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12944-024-02398-1","article-title":"Effects of Probucol on plasma amyloid-beta transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial","volume":"23","author":"Dang","year":"2024","journal-title":"Lipids Health Dis"},{"key":"2025111212300798000_45.46.e1388252025.30","doi-asserted-by":"crossref","first-page":"e0299764","DOI":"10.1371\/journal.pone.0299764","article-title":"Associations between regional blood-brain barrier permeability, aging, and Alzheimer's disease biomarkers in cognitively normal older adults","volume":"19","author":"Denkinger","year":"2024","journal-title":"PLoS One"},{"key":"2025111212300798000_45.46.e1388252025.31","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0333-5"},{"key":"2025111212300798000_45.46.e1388252025.32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.32.19053"},{"key":"2025111212300798000_45.46.e1388252025.33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/MOL.0000000000000801","article-title":"Lipids and brain inflammation in APOE4-associated dementia","volume":"33","author":"Duro","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"2025111212300798000_45.46.e1388252025.34","doi-asserted-by":"publisher","DOI":"10.3390\/cells8020182"},{"key":"2025111212300798000_45.46.e1388252025.35","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00742"},{"key":"2025111212300798000_45.46.e1388252025.36","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/alz.13703","article-title":"Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease","volume":"20","author":"Ferguson","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2025111212300798000_45.46.e1388252025.37","doi-asserted-by":"crossref","first-page":"106983","DOI":"10.1016\/j.nbd.2025.106983","article-title":"APOE4 reshapes the lipid droplet proteome and modulates microglial inflammatory responses","volume":"212","author":"Friday","year":"2025","journal-title":"Neurobiol Dis"},{"key":"2025111212300798000_45.46.e1388252025.38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13578-023-01120-5","article-title":"Integrative single-nucleus multi-omics analysis prioritizes candidate cis and trans regulatory networks and their target genes in Alzheimer's disease brains","volume":"13","author":"Gamache","year":"2023","journal-title":"Cell Biosci"},{"key":"2025111212300798000_45.46.e1388252025.39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000341299","article-title":"The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from Alzheimer's disease-like pathological features","volume":"12","author":"Ghosal","year":"2013","journal-title":"Neurodegener Dis"},{"key":"2025111212300798000_45.46.e1388252025.40","first-page":"110","article-title":"A randomized controlled study to evaluate the effect of bexarotene on amyloid-beta and apolipoprotein E metabolism in healthy subjects","volume":"2","author":"Ghosal","year":"2016","journal-title":"Alzheimers Dement"},{"key":"2025111212300798000_45.46.e1388252025.41","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25172"},{"key":"2025111212300798000_45.46.e1388252025.42","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal3222"},{"key":"2025111212300798000_45.46.e1388252025.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-019-0539-4"},{"key":"2025111212300798000_45.46.e1388252025.44","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1016\/j.ymthe.2024.11.003","article-title":"AAVrh.10 delivery of novel APOE2-Christchurch variant suppresses amyloid and Tau pathology in Alzheimer's disease mice","volume":"32","author":"Gunaydin","year":"2024","journal-title":"Mol Ther"},{"key":"2025111212300798000_45.46.e1388252025.45","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/jcph.853","article-title":"Phase 1 randomized, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics of a single escalating dose and repeated doses of CN-105 in healthy adult subjects","volume":"57","author":"Guptill","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2025111212300798000_45.46.e1388252025.46","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2015.44"},{"key":"2025111212300798000_45.46.e1388252025.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07185-7"},{"key":"2025111212300798000_45.46.e1388252025.48","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201901369RR"},{"key":"2025111212300798000_45.46.e1388252025.49","doi-asserted-by":"crossref","first-page":"577185","DOI":"10.1016\/j.jneuroim.2020.577185","article-title":"Microglia heterogeneity and neurodegeneration: the emerging paradigm of the role of immunity in Alzheimer's disease","volume":"341","author":"Hashemiaghdam","year":"2020","journal-title":"J Neuroimmunol"},{"key":"2025111212300798000_45.46.e1388252025.50","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505846"},{"key":"2025111212300798000_45.46.e1388252025.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01208-7"},{"key":"2025111212300798000_45.46.e1388252025.52","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3233\/JAD-200203","article-title":"Simple and fast assay for apolipoprotein E phenotyping and glycotyping: discovering isoform-specific glycosylation in plasma and cerebrospinal fluid","volume":"76","author":"Hu","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"2025111212300798000_45.46.e1388252025.53","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007000"},{"key":"2025111212300798000_45.46.e1388252025.54","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2024.0794"},{"key":"2025111212300798000_45.46.e1388252025.55","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2013.76"},{"key":"2025111212300798000_45.46.e1388252025.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2017.11.014"},{"key":"2025111212300798000_45.46.e1388252025.57","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0337-1"},{"key":"2025111212300798000_45.46.e1388252025.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.03.024"},{"key":"2025111212300798000_45.46.e1388252025.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105867"},{"key":"2025111212300798000_45.46.e1388252025.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2020.10.003"},{"key":"2025111212300798000_45.46.e1388252025.61","doi-asserted-by":"crossref","first-page":"647","DOI":"10.14283\/jpad.2023.105","article-title":"Fibrin-targeting immunotherapy for dementia","volume":"10","author":"Kantor","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"2025111212300798000_45.46.e1388252025.62","doi-asserted-by":"crossref","unstructured":"Kantor B , Odonovan B , Rittiner J , Hodgson D , Lindner N , Guerrero S , Dong W , Zhang A , Chiba-Falek O (2024a) All-in-one AAV-delivered epigenome-editing platform: proof-of-concept and therapeutic implications for neurodegenerative disorders. bioRxiv.","DOI":"10.1101\/2023.04.14.536951"},{"key":"2025111212300798000_45.46.e1388252025.63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50515-6"},{"key":"2025111212300798000_45.46.e1388252025.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2009.06.026"},{"key":"2025111212300798000_45.46.e1388252025.65","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20121274"},{"key":"2025111212300798000_45.46.e1388252025.66","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2017.48"},{"key":"2025111212300798000_45.46.e1388252025.67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06301-2"},{"key":"2025111212300798000_45.46.e1388252025.68","doi-asserted-by":"crossref","first-page":"146685","DOI":"10.1016\/j.brainres.2020.146685","article-title":"Apoe mimetic improves pathology and memory in a model of Alzheimer's disease","volume":"1733","author":"Krishnamurthy","year":"2020","journal-title":"Brain Res"},{"key":"2025111212300798000_45.46.e1388252025.69","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-8-18"},{"key":"2025111212300798000_45.46.e1388252025.70","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00435-y"},{"key":"2025111212300798000_45.46.e1388252025.71","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-020-00764-7"},{"key":"2025111212300798000_45.46.e1388252025.72","unstructured":"Lexeo Therapeutics (2024) Lexeo therapeutics announces positive interim data for LX1001, first-ever gene therapy to impact the underlying genetic cause of APOE4-associated Alzheimer\u2019s disease, at the clinical trials on Alzheimer\u2019s disease (CTAD) conference."},{"key":"2025111212300798000_45.46.e1388252025.73","doi-asserted-by":"crossref","unstructured":"Li B , Wang S , Kerman B , Hugo C , Shwab EK , Shu C , Chiba-Falek O , Arvanitakis Z , Yassine HN (2025) Microglial states are susceptible to senescence and cholesterol dysregulation in Alzheimer's disease. Aging Cell e70189 [Online ahead of print]. https:\/\/doi.org\/10.1111\/acel.70189","DOI":"10.1101\/2024.11.18.624141"},{"key":"2025111212300798000_45.46.e1388252025.74","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41419-019-1764-1","article-title":"cPLA2 activation contributes to lysosomal defects leading to impairment of autophagy after spinal cord injury","volume":"10","author":"Li","year":"2019","journal-title":"Cell Death Dis"},{"key":"2025111212300798000_45.46.e1388252025.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.03.014"},{"key":"2025111212300798000_45.46.e1388252025.76","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0646-14.2014"},{"key":"2025111212300798000_45.46.e1388252025.77","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96429"},{"key":"2025111212300798000_45.46.e1388252025.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2018.06.011"},{"key":"2025111212300798000_45.46.e1388252025.79","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2174\/1567205013666160404120817","article-title":"An anti-apoE4 specific monoclonal antibody counteracts the pathological effects of apoE4 in vivo","volume":"13","author":"Luz","year":"2016","journal-title":"Curr Alzheimer Res"},{"key":"2025111212300798000_45.46.e1388252025.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105615"},{"key":"2025111212300798000_45.46.e1388252025.81","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-019-0566-1"},{"key":"2025111212300798000_45.46.e1388252025.82","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1195-2"},{"key":"2025111212300798000_45.46.e1388252025.83","doi-asserted-by":"crossref","first-page":"102420","DOI":"10.1016\/j.stemcr.2025.102420","article-title":"An efficient, non-viral arrayed CRISPR screening platform for iPSC-derived myeloid and microglia models","volume":"20","author":"Meier","year":"2025","journal-title":"Stem Cell Reports"},{"key":"2025111212300798000_45.46.e1388252025.84","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01239-0"},{"key":"2025111212300798000_45.46.e1388252025.85","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.22073"},{"key":"2025111212300798000_45.46.e1388252025.86","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2247-3"},{"key":"2025111212300798000_45.46.e1388252025.87","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X20952012"},{"key":"2025111212300798000_45.46.e1388252025.88","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-022-01222-2"},{"key":"2025111212300798000_45.46.e1388252025.89","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13195-025-01795-7","article-title":"Increased cerebrospinal fluid and plasma apoE glycosylation is associated with reduced levels of Alzheimer\u2019s disease biomarkers","volume":"17","author":"Nedelkov","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"2025111212300798000_45.46.e1388252025.90","doi-asserted-by":"publisher","DOI":"10.1002\/glia.21004"},{"key":"2025111212300798000_45.46.e1388252025.91","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.225532"},{"key":"2025111212300798000_45.46.e1388252025.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.04.006"},{"key":"2025111212300798000_45.46.e1388252025.93","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13195-022-01028-1","article-title":"Effect of the ABCA1 agonist CS-6253 on amyloid-\u03b2 and lipoprotein metabolism in cynomolgus monkeys","volume":"14","author":"Noveir","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"2025111212300798000_45.46.e1388252025.94","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2015.04.020","article-title":"Lack of support for bexarotene as a treatment for Alzheimer's disease","volume":"100","author":"O'Hare","year":"2016","journal-title":"Neuropharmacology"},{"key":"2025111212300798000_45.46.e1388252025.95","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0085-z"},{"key":"2025111212300798000_45.46.e1388252025.96","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2014.00380"},{"key":"2025111212300798000_45.46.e1388252025.97","doi-asserted-by":"publisher","DOI":"10.1042\/bj3180797"},{"key":"2025111212300798000_45.46.e1388252025.98","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.immuni.2025.04.029","article-title":"Amyloid-\u03b2 induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer's disease","volume":"58","author":"Prakash","year":"2025","journal-title":"Immunity"},{"key":"2025111212300798000_45.46.e1388252025.99","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuroscience.2023.11.023","article-title":"Apoe mimic peptide COG1410 reduces Abeta deposition and improves cognitive function by inducing the transformation of A1\/A2 reactive astrocytes and increasing the BDNF concentration in brain of APP\/PS1 double transgenic mice","volume":"537","author":"Qiao","year":"2024","journal-title":"Neuroscience"},{"key":"2025111212300798000_45.46.e1388252025.100","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1400-19.2019"},{"key":"2025111212300798000_45.46.e1388252025.101","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/humc.2017.231","article-title":"AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer's disease","volume":"29","author":"Rosenberg","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"key":"2025111212300798000_45.46.e1388252025.102","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2020.06.010"},{"key":"2025111212300798000_45.46.e1388252025.103","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/17425247.2025.2480654","article-title":"The blood-brain barrier as a treatment target for neurodegenerative disorders","volume":"22","author":"Rust","year":"2025","journal-title":"Expert Opin Drug Deliv"},{"key":"2025111212300798000_45.46.e1388252025.104","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/brain\/awaf068","article-title":"The blood-brain barrier: a help and a hindrance","volume":"148","author":"Rust","year":"2025","journal-title":"Brain"},{"key":"2025111212300798000_45.46.e1388252025.105","doi-asserted-by":"crossref","unstructured":"Sadybekov AV , et al. (2025) Development of potent, selective cPLA2 inhibitors for targeting neuroinflammation in Alzheimer\u2019s disease and other neurodegenerative disorders. bioRxiv:2025.2003.2009.641748.","DOI":"10.1101\/2025.03.09.641748"},{"key":"2025111212300798000_45.46.e1388252025.106","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2011.11.036"},{"key":"2025111212300798000_45.46.e1388252025.107","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01124-1"},{"key":"2025111212300798000_45.46.e1388252025.108","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.51.30749"},{"key":"2025111212300798000_45.46.e1388252025.109","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008081"},{"key":"2025111212300798000_45.46.e1388252025.110","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/s41591-025-03835-z","article-title":"APOE \u03b54 carriers share immune-related proteomic changes across neurodegenerative diseases","volume":"31","author":"Shvetcov","year":"2025","journal-title":"Nat Med"},{"key":"2025111212300798000_45.46.e1388252025.111","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz4564"},{"key":"2025111212300798000_45.46.e1388252025.112","doi-asserted-by":"crossref","first-page":"6792","DOI":"10.3390\/jcm12216792","article-title":"Anti-amyloid therapy, AD, and ARIA: untangling the role of CAA","volume":"12","author":"Sin","year":"2023","journal-title":"J Clin Med"},{"key":"2025111212300798000_45.46.e1388252025.113","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115961"},{"key":"2025111212300798000_45.46.e1388252025.114","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-023-01334-3"},{"key":"2025111212300798000_45.46.e1388252025.115","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.08.037"},{"key":"2025111212300798000_45.46.e1388252025.116","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-018-0234-x"},{"key":"2025111212300798000_45.46.e1388252025.117","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00050.2017"},{"key":"2025111212300798000_45.46.e1388252025.118","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.05.017"},{"key":"2025111212300798000_45.46.e1388252025.119","doi-asserted-by":"crossref","first-page":"e20241232","DOI":"10.1084\/jem.20241232","article-title":"Lipid metabolism and neuroinflammation: what is the link?","volume":"222","author":"Tiwari","year":"2025","journal-title":"J Exp Med"},{"key":"2025111212300798000_45.46.e1388252025.120","doi-asserted-by":"crossref","first-page":"700847","DOI":"10.3389\/fphys.2021.700847","article-title":"Understanding the exchange of systemic HDL particles into the brain and vascular cells has diagnostic and therapeutic implications for neurodegenerative diseases","volume":"12","author":"Van Valkenburgh","year":"2021","journal-title":"Front Physiol"},{"key":"2025111212300798000_45.46.e1388252025.121","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2022.07.005"},{"key":"2025111212300798000_45.46.e1388252025.122","doi-asserted-by":"publisher","DOI":"10.1159\/000334914"},{"key":"2025111212300798000_45.46.e1388252025.123","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M508780200"},{"key":"2025111212300798000_45.46.e1388252025.124","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33622"},{"key":"2025111212300798000_45.46.e1388252025.125","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0004-z"},{"key":"2025111212300798000_45.46.e1388252025.126","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00577-1"},{"key":"2025111212300798000_45.46.e1388252025.127","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00549-5"},{"key":"2025111212300798000_45.46.e1388252025.128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13024-025-00802-7","article-title":"Cellular senescence induced by cholesterol accumulation is mediated by lysosomal ABCA1 in APOE4 and AD","volume":"20","author":"Wang","year":"2025","journal-title":"Mol Neurodegener"},{"key":"2025111212300798000_45.46.e1388252025.129","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/S0021-9258(18)34954-8","article-title":"Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site","volume":"257","author":"Weisgraber","year":"1982","journal-title":"J Biol Chem"},{"key":"2025111212300798000_45.46.e1388252025.130","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2023.11.010"},{"key":"2025111212300798000_45.46.e1388252025.131","doi-asserted-by":"crossref","first-page":"eadq6038","DOI":"10.1126\/sciadv.adq6038","article-title":"Reducing microglial lipid load enhances \u03b2 amyloid phagocytosis in an Alzheimer's disease mouse model","volume":"11","author":"Wu","year":"2025","journal-title":"Sci Adv"},{"key":"2025111212300798000_45.46.e1388252025.132","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0228-7"},{"key":"2025111212300798000_45.46.e1388252025.133","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.119.313169"},{"key":"2025111212300798000_45.46.e1388252025.134","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508693102"},{"key":"2025111212300798000_45.46.e1388252025.135","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16344"},{"key":"2025111212300798000_45.46.e1388252025.136","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4103\/NRR.NRR-D-23-01401","article-title":"Lipid droplets in the nervous system: involvement in cell metabolic homeostasis","volume":"20","author":"Zhang","year":"2025","journal-title":"Neural Regen Res"},{"key":"2025111212300798000_45.46.e1388252025.137","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2016.04.020"},{"key":"2025111212300798000_45.46.e1388252025.138","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000535131","article-title":"Brain lipids and lipid droplet dysregulation in Alzheimer's disease and neuropsychiatric disorders","volume":"9","author":"Zhao","year":"2023","journal-title":"Complex Psychiatry"}],"container-title":["The Journal of Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1523\/JNEUROSCI.1388-25.2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:08:34Z","timestamp":1762999714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jneurosci.org\/lookup\/doi\/10.1523\/JNEUROSCI.1388-25.2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":138,"journal-issue":{"issue":"46","published-online":{"date-parts":[[2025,11,12]]},"published-print":{"date-parts":[[2025,11,12]]}},"alternative-id":["10.1523\/JNEUROSCI.1388-25.2025"],"URL":"https:\/\/doi.org\/10.1523\/jneurosci.1388-25.2025","relation":{},"ISSN":["0270-6474","1529-2401"],"issn-type":[{"value":"0270-6474","type":"print"},{"value":"1529-2401","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}